# D2mbiotherapeutics

**Canonical:** https://apis.io/providers/d2mbiotherapeutics/  
**Website:** https://equityzen.com/company/d2mbiotherapeutics  
**APIs profiled:** 0

D2mbiotherapeutics (also known as D2M Biotherapeutics) is a clinical‑stage biotechnology company focused on developing innovative immuno‑oncology and autoimmune therapeutics. Leveraging human‑genetics driven discovery, the firm aims to create novel antibodies and cell therapies targeting unmet medical needs in cancer and inflammatory diseases. Based in Natick, MA, the company is advancing its pipeline through early‑stage clinical trials and seeks to expand its platform through strategic collaborations and funding.

## Kin Score — 3.4 / 100 (minimal)

Scored 2026-10-31 under rubric 0.25.0.

| Facet | Score |
|---|---|
| Discoverability | 44.6 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 4.7 (matched via tags).

## Agent readiness — 3.1 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | documented |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **D2Mbiotherapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Immuno-Oncology, Clinical Stage, Massachusetts

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/d2mbiotherapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.